Search

Search Constraints

You searched for: Author/Creator Kosiborod, Mikhail N.

Search Results

21. Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. (15th June 2020)

22. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. (29th July 2021)

23. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Issue 4 (26th January 2021)

24. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Issue 4 (6th November 2022)

25. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Issue 17 (27th April 2021)

26. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Issue 12 (22nd September 2020)

27. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Issue 6 (20th April 2022)

28. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Issue 13 (16th August 2022)

29. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF. (22nd August 2022)

30. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Issue 11 (23rd May 2022)